Long non-coding RNAs in metabolic diseases: from bench to bedside

Federica Rey; Gian Vincenzo Zuccotti; Stephana Carelli

doi:10.1016/j.tem.2021.05.009

Long non-coding RNAs in metabolic diseases: from bench to bedside

Trends Endocrinol Metab. 2021 Oct;32(10):747-749. doi: 10.1016/j.tem.2021.05.009. Epub 2021 Jun 19.

Authors

Federica Rey¹, Gian Vincenzo Zuccotti², Stephana Carelli³

Affiliations

¹ Department of Biomedical and Clinical Sciences, L. Sacco, University of Milan, Milan, Italy; Pediatric Clinical Research Center, Fondazione Romeo ed Enrica Invernizzi, University of Milan, Milan, Italy.
² Department of Biomedical and Clinical Sciences, L. Sacco, University of Milan, Milan, Italy; Pediatric Clinical Research Center, Fondazione Romeo ed Enrica Invernizzi, University of Milan, Milan, Italy; Department of Pediatrics, Children's Hospital V. Buzzi, Milan, Italy.
³ Department of Biomedical and Clinical Sciences, L. Sacco, University of Milan, Milan, Italy; Pediatric Clinical Research Center, Fondazione Romeo ed Enrica Invernizzi, University of Milan, Milan, Italy. Electronic address: Stephana.carelli@unimi.it.

PMID: 34158225
DOI: 10.1016/j.tem.2021.05.009

Abstract

Long non-coding RNAs (lncRNAs) are being widely studied for their implications in physiological and diseases contexts but their functions and therapeutic potentials in metabolic diseases are far from clarified. Here, we report a summary of current advances in lncRNAs identification, functions, role as biomarkers and therapeutic prospects in metabolic diseases.

Keywords: biomarkers; clinical trials; lncRNAs; metabolic diseases; obesity; target/RNA therapy.

MeSH terms

Humans
Metabolic Diseases* / genetics
RNA, Long Noncoding* / genetics

Substances

RNA, Long Noncoding